UPFRONT™ -
A Clinical Trial for
Patients with Newly
Diagnosed Multiple
Myeloma
| Multiple myeloma is the second most common cancer of the blood. The UPFRONT™ trial will study the addition of VELCADE® to 3 active drug therapies presently being used to treat multiple myeloma. |
 
|
To learn more about the Millennium drug used in this trial, please CLICK HERE |
© 2009 Millennium Pharmaceuticals, Inc. |